Dr. Reddy's Launches Imatinib Mesylate Tablets In U.S. - Quick Facts

Shutterstock photo

(RTTNews.com) - Dr. Reddy's Laboratories Ltd. (RDY) announced the launch of Imatinib Mesylate Tablets, USP, a therapeutic equivalent generic version of Gleevec Tablets in the U.S. market approved by the U.S. Food and Drug Administration.

According to IMS Health, Gleevec brand and generic had U.S. sales of approximately $868 million MAT for the most recent twelve months ending in July 2018. Gleevec is a trademark of Novartis Pharmaceuticals Corp.

Dr. Reddy's Imatinib Mesylate Tablets, USP is available in 100 mg 30 count bottle size and 400 mg 90 count bottle size.

Read the original article on RTTNews (http://www.rttnews.com/2939444/dr-reddy-s-launches-imatinib-mesylate-tablets-in-u-s-quick-facts.aspx)

For comments and feedback: contact editorial@rttnews.com

This article appears in: World Markets , Stocks , Economy

More from RTT News


See All RTT news

Research Brokers before you trade

Want to trade FX?